“I wasn't surprised by the result.” Call it the Joao Factor. Fonseca only fed that frenzy in his press conference. “When I arrived here, my first goal was to qualify for the main draw,” he ...

Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways ...

These data reinforced our INDUKINE TM design, establishing that we could reproducibly improve the therapeutic index in an outpatient setting with a potentially best-in-class profile for WTX-124 ...

FormFactor’s FORM shares have lost 26.1% in the trailing six months, underperforming the broader Zacks Computer and Technology sector’s return of 3.7% and the Zacks Electronics- Semiconductors ...